Australian anticancer research presented at FIP conference

A prototype of a new class of well-tolerated anticancer agents, called CTU, has been developed by pharmaceutical scientists in Australia, and the research presented at the FIP conference. Research showing the effect of the CTU prototype, in an animal model of breast cancer and on a human breast cancer cell line, was presented today at